Clarient's Insight Dx Pulmotax assay could predict which non-small cell lung cancer (NSCLC) patients will respond to taxane chemotherapy, a study has suggested. Taxanes are commonly used to treat several types of cancer, and improve patient response rates but also cause severe side-effects ...
Please Login to read the full article.
